Evaluation of the effect of tofacitinib exposure on outcomes in kidney transplant patients

American Journal of Transplantation

Volumn 15, Issue 6, 2015, Pages 1644-1653

  Vincenti, F ^a   Silva, H T ^b   Busque, S ^c   O'Connell, P J ^d   Russ, G ^e   Budde, K ^f   Yoshida, A ^g   Tortorici, M A ^h   Lamba, M ^h   Lawendy, N ^h   Wang, W ^h   Chan, G ^h  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HOSPITAL DO RIM E HIPERTENSÃO   (Brazil)

^c STANFORD UNIVERSITY   (United States)

^d WESTMEAD HOSPITAL   (Australia)

^e ROYAL ADELAIDE HOSPITAL   (Australia)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g HENRY FORD HOSPITAL   (United States)

^h PFIZER INC   (United States)

Author keywords

clinical research practice; immunosuppressive regimens; kidney transplantation nephrology; pharmacokinetics pharmacodynamics

Indexed keywords

BASILIXIMAB; CORTICOSTEROID; CYCLOSPORIN A; LYMPHOCYTE ANTIBODY; MYCOPHENOLIC ACID; TOFACITINIB; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; PIPERIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; DRUG DOSE REGIMEN; FEMALE; FIXED DOSE REGIMEN; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KAPLAN MEIER METHOD; KIDNEY BIOPSY; KIDNEY FIBROSIS; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; KIDNEY TUBULE ATROPHY; KIDNEY TUBULE DISORDER; MAJOR CLINICAL STUDY; MALE; MICROEMULSION; MIDDLE AGED; MULTICENTER STUDY (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POST HOC ANALYSIS; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RISK BENEFIT ANALYSIS; RISK FACTOR; TREATMENT OUTCOME; YOUNG ADULT; BIOPSY; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECTS; GLOMERULUS FILTRATION RATE; GRAFT REJECTION; KIDNEY; LYMPHOPROLIFERATIVE DISORDERS; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT;

ADULT; BIOPSY; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; PIPERIDINES; PYRIMIDINES; PYRROLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; RISK FACTORS;

EID: 84929501985     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.13181     Document Type: Article

References (23)

1. Ghoreschi K, Jesson MI, Li X, et al., Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol 2011; 186: 4234-4243.
2. Meyer DM, Jesson MI, Li X, et al., Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J Inflamm (Lond) 2010; 7: 41.
3. Burmester GR, Blanco R, Charles-Schoeman C, et al., Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: A randomised phase 3 trial. Lancet 2013; 381: 451-460.
4. Fleischmann R, Kremer J, Cush J, et al., Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 2012; 367: 495-507.
5. Kremer J, Li ZG, Hall S, et al., Tofacitinib in combination with nonbiologic DMARDs in patients with active rheumatoid arthritis: A randomized trial. Martin-Mola E 2013; 159: 253-261.
6. van der Heijde D, Tanaka Y, Fleischmann R, et al., Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum 2013; 65: 559-570.
7. van Vollenhoven RF, Fleischmann R, Cohen S, et al., Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 2012; 367: 508-519.
8. Lee EB, Fleischmann R, Hall S, et al., Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med 2014; 370: 2377-2386.
9. Papp KA, Menter A, Strober B, et al., Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: A Phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol 2012; 167: 668-677.
10. Sandborn WJ, Ghosh S, Panes J, et al., Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med 2012; 367: 616-624.
11. Busque S, Leventhal J, Brennan DC, et al., Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690,550: A pilot study in de novo kidney allograft recipients. Am J Transplant 2009; 9: 1936-1945.
12. Vincenti F, Tedesco SH, Busque S, et al., Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: Efficacy, renal function and safety at 1 year. Am J Transplant 2012; 12: 2446-2455.
13. Dowty ME, Lin J, Ryder TF, et al., The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a Janus kinase inhibitor, in humans. Drug Metab Dispos 2014; 42: 759-773.
14. Cox DR,. Regression models and life-tables. Journal of the Royal Statistical Society Series B (Methodological) 1972; 34: 187-220.
15. Fox J,. Cox Proportional-hazards regression for survival data. In:, Fox J, Monette G, editors, R and S-Plus companion to applied regression. Thousand Oaks: Sage Publications, Inc. 2002.
16. Chapman JR,. Chronic calcineurin, inhibitor use, is nephrotoxic. Clin Pharmacol Ther 2011; 90: 207-209.
17. Matas AJ,. Calcineurin inhibitors: Short-term friend, long-term foe? Clin Pharmacol Ther 2011; 90: 209-211.
18. Vincenti F, Ramos E, Brattstrom C, et al., Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation 2001; 71: 1282-1287.
19. Flechner SM, Glyda M, Cockfield S, et al., The ORION study: Comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients. Am J Transplant 2011; 11: 1633-1644.
20. Eckhoff DE, Young CJ, Gaston RS, et al., Racial disparities in renal allograft survival: A public health issue? J Am Coll Surg 2007; 204: 894-902.
21. Narayanan M, Pankewycz O, El-Ghoroury M, et al., Outcomes in African American kidney transplant patients receiving tacrolimus and mycophenolic acid immunosuppression. Transplantation 2013; 95: 566-572.
22. Nankivell BJ, Fenton-Lee CA, Kuypers DR, et al., Effect of histological damage on long-term kidney transplant outcome. Transplantation 2001; 71: 515-523.
23. Vincenti F, Charpentier B, Vanrenterghem Y, et al., A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010; 10: 535-546.